Logo image of AGRX

AGILE THERAPEUTICS INC (AGRX) Stock Price, Quote, News and Overview

NASDAQ:AGRX - Nasdaq - US00847L3087 - Common Stock - Currency: USD

0.6022  +0.06 (+10.11%)

After market: 0.2408 -0.36 (-60.01%)

AGRX Quote, Performance and Key Statistics

AGILE THERAPEUTICS INC

NASDAQ:AGRX (3/25/2024, 8:08:50 PM)

After market: 0.2408 -0.36 (-60.01%)

0.6022

+0.06 (+10.11%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High11.5
52 Week Low0.5
Market Cap1.51M
Shares2.51M
Float0
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE0.89
Earnings (Next)05-09 2024-05-09/bmo
IPO05-22 2014-05-22


AGRX short term performance overview.The bars show the price performance of AGRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

AGRX long term performance overview.The bars show the price performance of AGRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AGRX is 0.6022 USD. In the past month the price decreased by -25.49%. In the past year, price decreased by -94.62%.

AGILE THERAPEUTICS INC / AGRX Daily stock chart

AGRX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 68.04 838.54B
JNJ JOHNSON & JOHNSON 15.38 372.51B
NVO NOVO-NORDISK A/S-SPONS ADR 17.99 275.58B
NVS NOVARTIS AG-SPONSORED ADR 14.12 221.49B
AZN ASTRAZENECA PLC-SPONS ADR 16.76 215.69B
MRK MERCK & CO. INC. 10.62 208.21B
PFE PFIZER INC 7.37 129.99B
SNY SANOFI-ADR 13.59 128.08B
BMY BRISTOL-MYERS SQUIBB CO 6.53 97.47B
GSK GSK PLC-SPON ADR 8.6 75.84B
ZTS ZOETIS INC 25.92 68.46B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.67 47.30B

About AGRX

Company Profile

AGRX logo image Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Company Info

AGILE THERAPEUTICS INC

500 College Road East, Suite 310

Princeton NEW JERSEY 08540 US

CEO: Alfred Altomari

Employees: 22

Company Website: https://www.agiletherapeutics.com/

Phone: 16096831880

AGILE THERAPEUTICS INC / AGRX FAQ

What is the stock price of AGILE THERAPEUTICS INC today?

The current stock price of AGRX is 0.6022 USD. The price increased by 10.11% in the last trading session.


What is the ticker symbol for AGILE THERAPEUTICS INC stock?

The exchange symbol of AGILE THERAPEUTICS INC is AGRX and it is listed on the Nasdaq exchange.


On which exchange is AGRX stock listed?

AGRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AGILE THERAPEUTICS INC stock?

7 analysts have analysed AGRX and the average price target is 5.1 USD. This implies a price increase of 746.89% is expected in the next year compared to the current price of 0.6022. Check the AGILE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AGILE THERAPEUTICS INC worth?

AGILE THERAPEUTICS INC (AGRX) has a market capitalization of 1.51M USD. This makes AGRX a Nano Cap stock.


How many employees does AGILE THERAPEUTICS INC have?

AGILE THERAPEUTICS INC (AGRX) currently has 22 employees.


What are the support and resistance levels for AGILE THERAPEUTICS INC (AGRX) stock?

AGILE THERAPEUTICS INC (AGRX) has a resistance level at 0.75. Check the full technical report for a detailed analysis of AGRX support and resistance levels.


Is AGILE THERAPEUTICS INC (AGRX) expected to grow?

The Revenue of AGILE THERAPEUTICS INC (AGRX) is expected to grow by 101% in the next year. Check the estimates tab for more information on the AGRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AGILE THERAPEUTICS INC (AGRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AGILE THERAPEUTICS INC (AGRX) stock pay dividends?

AGRX does not pay a dividend.


When does AGILE THERAPEUTICS INC (AGRX) report earnings?

AGILE THERAPEUTICS INC (AGRX) will report earnings on 2024-05-09, before the market open.


What is the Price/Earnings (PE) ratio of AGILE THERAPEUTICS INC (AGRX)?

AGILE THERAPEUTICS INC (AGRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.33).


AGRX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AGRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AGRX. Both the profitability and financial health of AGRX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AGRX Financial Highlights

Over the last trailing twelve months AGRX reported a non-GAAP Earnings per Share(EPS) of -13.33. The EPS increased by 97.64% compared to the year before.


Industry RankSector Rank
PM (TTM) 41.26%
ROA 75.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%98.98%
Sales Q2Q%122%
EPS 1Y (TTM)97.64%
Revenue 1Y (TTM)137.74%

AGRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to AGRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 93.92% and a revenue growth 101% for AGRX


Ownership
Inst Owners0.07%
Ins Owners105.84%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.86
Price Target5.1 (746.89%)
EPS Next Y93.92%
Revenue Next Year101%